Effects of levetiracetam tablets and carbamazepine tablets in the treatment of refractory epilepsy
Objective To analyze the effects of oral treatment of levetiracetam tablets and carbamazepine tablets on clinical symptoms in patients with refractory epilepsy.Methods A total of 100 patients with refractory epilepsy admitted in our hospital from January 2020 to December 2021 were selected as the research objects and randomly divided into carbamazepine tablets group(50 cases,oral treatment of carbamazepine tablets)and levetiracetam tablets group(50 cases,oral treatment of levetiracetam tablets).The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the levetiracetam tablets group was significantly higher than that in the carbamazepine tablets group(P<0.05).Before treatment,there were no significant difference in seizure frequency,duration and EEG frequency between the two groups(P>0.05);after treatment,the seizure frequency,duration and EEG frequency θ and δ of the levetiracetam tablets group were significantly lower than those of the carbamazepine tablets group,and the EEG frequency α was significantly higher than that of the carbamazepine tablets group(P<0.05).Before treatment,there were no significant difference in the levels of immunoglobulin A(IgA),immunoglobulin G(IgG)and immunoglobulin M(IgM)between the two groups(P>0.05);after treatment,the levels of IgA,IgG and IgM in the levetiracetam tablets group were significantly higher than those in the carbamazepine tablets group(P<0.05).Before treatment,there were no significant difference in the levels of S-100β protein,myelin basic protein(MBP),neuron-specific enolase(NSE)and brain-derived neurotrophic factor(BDNF)between the two groups(P>0.05);after treatment,the levels of S-100β protein,MBP and NSE in the levetiracetam tablets group were significantly lower than those in the carbamazepine tablets group,and the level of BDNF was significantly higher than that in the carbamazepine tablets group(P<0.05).The total incidence of adverse drug reactions in the levetiracetam tablets group was significantly lower than that in the carbamazepine tablets group(P<0.05).Conclusion The levetiracetam tablets in the treatment of patients with refractory epilepsy has higher clinical application value.
NETL
NSTL
万方数据
维普
